07:00 , Oct 22, 2012 |  BC Week In Review  |  Clinical News

Iprivask: Phase IV data

The open-label, single-arm, U.S. Phase IV DESIR-ABLE trial in 516 patients who required anticoagulation after major surgery or due to a medical illness with prolonged immobility showed that twice-daily 15 mg subcutaneous desirudin led to...
08:00 , Dec 5, 2011 |  BC Week In Review  |  Company News

Basilea infectious, dermatology news

In October, HBM asked for the meeting and proposed four nominees "to support the evaluation and implementation of strategic decisions and to unlock Basilea's untapped potential." HBM subsequently lowered the number of its nominees to...
01:45 , Nov 30, 2011 |  BC Extra  |  Company News

Basilea bolsters board

Shareholders of Basilea Pharmaceutica AG (SIX:BSLN) elected three additional directors to the biotech's five-member board Tuesday at a meeting requested by shareholder HBM BioVentures. The new members are: Thomas Rinderknecht, chairman of cardiovascular company Canyon...
07:00 , Oct 31, 2011 |  BC Week In Review  |  Company News

Basilea infectious, dermatology news

Basilea scheduled the extraordinary general meeting requested by HBM Ventures for Nov. 29 to consider election to expand the company's board. Following discussions between Basilea and HBM, HBM is proposing to add three independent directors....
07:00 , Oct 10, 2011 |  BC Week In Review  |  Company News

Basilea infectious, dermatology news

HBM BioVentures said it is seeking to add four independent directors to Basilea's five-member board. HBM, which is Basilea's largest shareholder with an 18% stake, proposed the nominees "to support the evaluation and implementation of...
07:00 , Oct 10, 2011 |  BioCentury  |  Finance

Brawnier for deals

HBM BioVentures Ltd. 's proposal to expand the board of Basilea Pharmaceutica AG (SIX:BSLN) signals that the Swiss biotech's largest shareholder hopes partnerships will accompany the clinical data expected over the next year. HBM CEO...
00:46 , Oct 7, 2011 |  BC Extra  |  Company News

HBM seeks expanded Basilea board

HBM BioVentures said Thursday it is seeking to add four independent directors to the five-member board of Basilea Pharmaceutica AG (SIX:BSLN). HBM, which is Basilea's largest shareholder with an 18% stake, proposed the nominees "to...
07:00 , May 9, 2011 |  BC Week In Review  |  Clinical News

Desirudin cardiovascular data

In a post-hoc analysis of 1,565 evaluable patients in a double-blind, active-controlled, international Phase III trial showed that 15 mg desirudin twice daily reduced major VTE vs. enoxaparin regardless of renal impairment. Specifically, desirudin reduced...
07:00 , Apr 26, 2010 |  BC Week In Review  |  Clinical News

Iprivask desirudin: Phase IIIb data

In the open-label Phase IIIb PREVENT-HIT trial in 16 patients with clinically suspected HIT, no cases of thrombosis or major bleeding occurred in patients treated with fixed doses of 15 or 30 mg subcutaneous Iprivask...
08:00 , Mar 8, 2010 |  BC Week In Review  |  Company News

Canyon Pharmaceuticals sales and marketing update

Canyon Pharmaceuticals launched Iprivask desirudin in the U.S. to prevent deep vein thrombosis (DVT) in patients undergoing hip replacement surgery. The wholesale acquisition cost (WAC) for the direct thrombin inhibitor is $150 per vial. Canyon...